Legal, Devices & Diagnostics Natera fires more shots in ongoing patent battle with CareDx By Amanda James
Devices & Diagnostics, Legal Jury orders Natera to pay $44.9M in damages to CareDx for false advertising By Emma Bardin
Startups, Diagnostics Five things you need to know about prenatal testmaker Natera’s $175M IPO By Meghana Keshavan
Daily Prenatal diagnostics maker Natera raises $55M, pivoting into precision medicine By Meghana Keshavan
Devices & Diagnostics California startup Natera aims to redefine prenatal testing by analyzing DNA fragments By Arundhati Parmar
MedCity Influencers, Devices & Diagnostics, BioPharma It’s time to integrate liquid biopsy into colorectal cancer treatment decision-making By Dr. Takayuki Yoshino
BioPharma, Diagnostics Guardant Health study shows liquid biopsy picking up more mutations, delivering faster results By Alaric DeArment
Diagnostics, Startups First flushable pregnancy test gets pre-market approval from FDA By Stephanie Baum
